UCB SA (UCBJF)

Market Cap	52.82B +59.8%
Revenue (ttm)	9.09B +25.8%
Net Income	1.83B +46.3%
EPS	9.43 +46.5%
Shares Out	n/a
PE Ratio	28.87
Forward PE	22.19
Dividend	1.45 (0.50%)
Ex-Dividend Date	May 4, 2026

Volume	643
Average Volume	533
Open	286.59
Previous Close	283.89
Day's Range	281.55 - 286.59
52-Week Range	175.75 - 345.39
Beta	0.17
RSI	45.66
Earnings Date	Jul 30, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seiz...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1925
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: UCBJF

Financial Performance

In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.

Financial numbers in EUR